

Expression of Human Cytokine Genes Associated with Chronic Hepatitis B Disease Progression

Shuaibu Abdullahi Hudu^{1,2}, Mohd Taib Niazlin¹, Syafinaz Amin Nordin¹, Mohammed Ibrahim Saeed³, Soek Siam Tan⁴, Zamberi Sekawi^{1*}

¹Department of Medical Microbiology and Parasitology, Faculty of Medicine and Health Sciences, University Putra, Malaysia, ²Department of Medical Microbiology and Parasitology, Faculty of Basic Medical Sciences, College of Health Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria, ³Department of Medical Microbiology, Faculty of Medical Laboratory Sciences, National Ribat University, Buri, Khartoum, Sudan, ⁴Department of Hepatology, Selayang Hospital, Malaysia

ABSTRACT

Background: Hepatitis viruses are non-cytopathic viruses that lead to the infection and pathogenesis of liver diseases as a result of immunologically mediated event. **Objective:** To investigate the expression of human inflammatory cytokines in chronic hepatitis B patients according to the severity of the infection. **Methods:** We recruited a total of 120 patients, 40 of whom from cirrhotic, 40 non-cirrhotic, and 40 acute flare chronic hepatitis B and 40 healthy controls. For all groups total cellular RNA was extracted from whole blood samples, genomic DNA was eliminated, and cDNA was synthesized using the RT2 first strand kit, as instructed by the manufacturer. The real-time profiler PCR array was performed on an a master cycler ep realplex and the data were analyzed using an online data analysis software. **Results:** Non-cirrhotic chronic hepatitis B patients were found to significantly upregulate interleukin 10 receptors that regulate the balance between T helpers 1 and 2. On the other hand, patients with cirrhosis were found to have significant upregulated interleukin 3 gene expression. **Conclusion:** Our finding suggests that upregulation of anti-inflammatory and downregulation of pro-inflammatory cytokines may play a roles in the progression of non-cirrhotic chronic hepatitis B patients to cirrhotic and acute flare. However, a multi-center study with a larger sample size is needed to confirm our findings.

Hudu SA, et al. Iran J Immunol. 2017; 14(4):281-292.

Keywords: Acute Flare, Hepatitis B, Inflammatory Cytokines, Interleukins, Liver Cirrhosis

*Corresponding author: Dr. Zamberi Sekawi, Department of Medical Microbiology and Parasitology, Faculty of Medicine and Health Sciences, University Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia, e-mail: zamberi@upm.edu.my

INTRODUCTION

Acute and chronic liver infections are mostly characterized by the expression of pro- and anti-inflammatory cytokines, which lead to many inflammatory diseases of the liver, fibrosis, and subsequent cirrhosis of the liver. These cytokines are regulatory peptides that are pleiotropic in nature and can be produced by nearly every nucleated cell in the body, including hepatocytes (1,2). Cytokine family is composed of several subfamilies, such as the interleukins (ILs), tumor necrotic factors (TNFs), interferons (IFNs), chemokines, and interleukin 6-type cytokines. Recently, there have been increasing lines of evidence supporting the major role of several inflammatory cytokines in liver disease progression and tissue repair (3,4), including the current study. The cytokine families that are considered as the key factors in various stages of liver diseases include the pro-inflammatory molecule TNF- α , the anti-inflammatory cytokine IL-10, and the adipokine adiponectin; these cytokines also correlates with biomarkers of autoimmunity (5).

Hepatitis B virus (HBV) and hepatitis C virus are among numerous viruses affecting the human liver and are distinct because of their phenomenal capacity to cause persistent infection, cirrhosis, and hepatocellular carcinoma (HCC). Hepatitis B, C, and E are non-cytopathic viruses as such the outcome of infection and the pathogenesis of liver diseases are the result of immunologically mediated events. Adaptive immune response mediates almost all of the liver pathology associated with viral hepatitis, as evidenced by the fact that the hepatic immunopathology is induced by antigen-nonspecific inflammatory cells exacerbating cytotoxic T lymphocytes (CTLs) and the accumulation of CTLs in the liver. This study aimed to study the expression of human inflammatory cytokine genes in chronic hepatitis B patients related to the severity of the infection.

MATERIALS AND METHODS

Patients. This study is an analytical cross-section trial involving three disease groups (cirrhotic, non-cirrhotic, and acute flare chronic hepatitis B) and one healthy control group. Patients were recruited consecutively from the Hepatology Department, Selayang Hospital, Selangor, which serves as a tertiary referral center for hepatology cases in Malaysia. The control group included healthy volunteers of similar ages and racial origin to the disease groups. In this work, 10 mL of blood was collected from each patient using an EDTA blood tube and kept at -80°C prior to experiments. Next, 20 samples were collected from each group of chronic non-cirrhotic, cirrhotic, and acute flare chronic hepatitis B patients and healthy controls using computer-generated random number online software (<https://www.randomizer.org/>). The severity of a disease is defined as the extent of organ or system damage or its physiological decompensation of the patient's condition.

Total RNA Extraction. Total cellular RNA was extracted from the patient's whole blood using the QIAamp RNA blood mini kit, as described by the manufacturer (Qiagen, Hilden, Germany). Concisely, 20 μ l of the protease was added to the bottom of a 1.5 ml tube, followed by the addition of 200 μ l plasma. Buffer AL was added to all samples and was mixed thoroughly for 15 sec and incubated for 10 min at 56°C. Ethanol (200 μ l) was added to the sample and vortexed for 15 sec. The mixture was centrifuged at 10000 \times g for 60 min, followed by washing it using AW1 and AW2 buffers. The RNA

was then eluted by adding 50 μ l of elution buffer and stored at -70°C . The extracted RNA was subjected to purity and concentration checks.

cDNA Synthesis Using an RT2 First Strand Kit. The RT2 first strand kit was used for cDNA synthesis according to manufacturer's guidelines (Qiagen, Hilden, Germany). Briefly, a reverse transcription mixture was prepared by adding 4 μ l of Buffer BC3 x 5, 1 μ l of Control P2, 3 μ l of RNase free water, and 2 μ l of reverse transcriptase RE3 mix. This reverse transcription mixture (10 μ l) was then added to the genomic elimination mixture (10 μ l) and mixed by pipetting, and then was incubated for 15 min at a temperature of 42°C ; the reaction was immediately stopped by incubating at 95°C for 5 min. To each reaction mixtures, 91 μ l of RNase-free water was added and mixed by pipetting it for several times; before placing the mixture on ice and prior to real-time PCR, it was stored at -30°C .

Real-time Profiler PCR Array. The RT2 SYBR green master mix was briefly centrifuged. This master mix contained hot-start polymerase. The PCR component for real-time PCR for 96-wells was prepared by mixing 1350 μ l of RT2 SYBR green x 2 master mix, 1248 μ l RNase-free water, and 10^2 μ l cDNA synthesis reagent in a 14 ml tube. The RT2 profiler PCR array was carefully removed from its sealed packaging and 25 μ l of the PCR component mixture was added to each of the wells by changing tips to avoid cross-contamination. An optical thin wall cap was then used to seal the microplate, followed by centrifuging it briefly for 1 min at $1000 \times g$ to remove bubbles. The plate was placed on an Eppendorf master cycler ep realplex (Eppendorf, Canada) and the cycling conditions were set to 95°C for 10 min, 95°C for 15 sec, and 60°C for 1 min for 40 cycles. The threshold cycle (CT) value for each of the samples was then calculated using the real-time PCR cycler software. The threshold was set manually at 140 using the log view of the amplification plot.

Statistical Analysis. The Ct values were exported to an excel spreadsheet and the data were analyzed using SABioscience online data analysis software. A Multi-Gene qPCR Assay was also chosen. The MS Excel file containing the PCR data was then uploaded. In the "Basic Setup" section, samples were assigned to different groups including Group 1 (non-cirrhotic chronic hepatitis B patients), Group 2 (cirrhotic CHB patients), Group 3 (CHB patient with acute flare), and a control group (healthy individuals). The "Data QC" section was reviewed to assess each groups' PCR reproducibility, reverse transcription efficiency, and the presence of genomic DNA contamination. Housekeeping Genes were selected for data normalization by clicking the appropriate checkboxes. The data were then analyzed by clicking on the "analyze" button. The "Average Ct", " $2^{-\text{Ct}}$ ", "Fold Change", "p-value", and "Fold Regulation" sections for the results were processed by the software using the imported data.

RESULTS

The results from the clinically diagnosed chronic hepatitis B patients who have never undergone HBV treatment (Group 1), cirrhotic patients with liver stiffness score of more than 11 KPa (Group 2), and acute flare chronic hepatitis B patients with elevated serum ALT more than 5 times higher than the upper normal limit (Group 3) were compared with healthy normal control group that is HBsAg negative. Cytokine gene expression results showed that, out of the 84 genes (Supplementary) associated with inflammatory pathways that were tested, only 7 (8.3%) were expressed in non-cirrhotic

chronic hepatitis B patients compared to the healthy hepatitis B negative control group. On the other hand, gene expression was high among the cirrhotic and acute flare chronic hepatitis B groups in which 75 (89.3%) and 68 (81%) genes were expressed, respectively.

Patients with non-cirrhotic chronic hepatitis B infection were found to have significant upregulation of the interleukin 10 receptors (IL-10R) 1 and 2 ($p < 0.05$), while acute flare and cirrhotic chronic hepatitis B infection were found to have the highest number of upregulated genes (Table 1).

This observation is explained by the fact that the upregulated genes, mostly pro-inflammatory chemokines such as Chemokine (C-C motif) ligands (CCL) and also interleukin receptor one (IL-1R1), might play a significant role in acute flaring in chronic hepatitis B patients. Besides, non-cirrhotic chronic hepatitis B infected patient showed significant downregulation of only CCR6 ($p < 0.05$), whereas cirrhotic and acute flare chronic hepatitis B infected patients showed downregulation of several anti-inflammatory cytokine genes such as interleukin 13 and 17, interleukin 1 receptor antagonist (IL-1RN), and gamma interferon (Table 1).




Figure 1. Up-regulated genes (red cycles) are in the non-cirrhotic (group 1) patients as well as a significantly down-regulated gene (green cycle). The other genes (black cycles) were also up- and down-regulated but their expression is not significant when compared with the normal control group. The central lines indicate unchanged gene expression, while genes that are over-expressed are above the line and under-expressed genes are below the line.

The delta Ct values for each gene in the control and disease groups with p-values less than 0.05 are indicated in red in a scattered plot for non-cirrhotic (Fig. 1), cirrhotic (Fig. 2), and acute flare chronic hepatitis B (Fig. 3) patients. The scattered plot compares the normalized expression of every gene on the array between the two groups plotted together in order to quickly visualize large changes in gene expression. A fold-change ($2^{-\Delta Ct}$) was obtained by dividing the normalized gene expression in the disease sample

with the normalized gene expression of the control sample. Fold change values greater than unity represent an up-regulation.




Figure 2. Up-regulated (red cycles) and down-regulated genes (green cycle) in the cirrhotic (group 2) patients. The central lines indicate unchanged gene expression, while genes that are over-expressed are above the line and under-expressed genes are below the line.

This change is equal to the fold regulation in a biologically meaningful way. Similarly, fold change values less than the unity indicate downregulation, for which the fold regulation is the negative inverse of the fold-change.




Figure 3. Scattered plot of the expressed genes in the acute flare (group 3) patients. Significantly up-regulated (red cycles) and down-regulated genes (green cycle), while the remaining (black cycles) show no significant difference with the control group. The central lines indicate unchanged gene expression, while genes that are over-expressed are above the line and under-expressed genes are below the lines.

Table 1. Up and Down-regulated cytokines expression as compared to normal control group

Upregulated Cytokines			Down regulated Cytokines		
Non-cirrhotic	Cirrhotic	Acute	Non-cirrhotic	Cirrhotic	Acute flare
CHB	CHB	flare	CHB	CHB	
CD40LG	CCL26	CCL1	CCR6	BMP2	C5
CSF3	CCL4	CCL16		C5	CCL11
CX3CL1	CCR2	CCL17		CCL1	CCL13
IL-10RA	CXCL9	CCL26		CCL11	CCL15
IL-10RB	IL-3	CCL3		CCL13	CCL2
	TNFSF13	CCL4		CCL15	CCL20
		CCL7		CCL16	CCL22
		CCR2		CCL17	CCL23
		CCR4		CCL2	CCL24
		CCR5		CXCL12	IFNA2
		IL-1R1		CXCL13	IFNG
				CXCL2	IL15
				CXCL3	IL17A
				CXCL5	IL17C
				CXCL6	IL17F
				CXCR1	IL1A
				CXCR2	IL1B
				FASLG	IL1RN
				IFNA2	IL21
				IL10RB	IL27
				IL15	IL3
				IL16	IL33
				IL17A	IL5
				IL17C	IL5RA
				IL17F	IL7
				IL1A	IL9
				IL1B	IL9R
				IL1R1	TNF
				IL1RN	TNFRSF11B
				IL21	TNFSF10
				IL27	TNFSF11
				IL33	TNFSF13
				IL5	TNFSF13B
				IL5RA	TNFSF4
				IL7	VEGFA
				CXCL8	
				IL9	

CCR6: Chemokine (c-c motif) receptor 6; CD40LG: Cluster of differentiation 40 ligand; CSF3: Colony stimulating factor 3; CX3CL1: Chemokine C-X3-C motif ligand 1; IL-10RA: Interleukin 10 receptor alpha; IL-10RB: Interleukin 10 receptor beta; CCL26: Chemokine (C-C motif) ligand 26; CCL4: Chemokine (C-C motif) ligand 4; CCR2: Chemokine (C-C motif) receptor 2; CXCL9: Chemokine (C-X-C motif) ligand 9; IL-3: Interleukin 3; TNFSF13: Tumour necrosis factor (ligand) superfamily, member 13; CCL1: Chemokine (C-C motif) ligand 1; CCL16: Chemokine (C-C motif) ligand 16; CCL17: Chemokine (C-C motif) ligand 17; CCL3: Chemokine (C-C motif) ligand 3; CCL7: Chemokine (C-C motif) ligand 7; CCR4: Chemokine (C-C motif) receptor 4; CCR5: Chemokine (C-C motif) receptor 5; IL-1R1: Interleukin 1 receptor type 1

The fold-change was found to be higher in the liver cirrhotic group in relation to the expressed genes ($p < 0.05$). The results of the average Ct values show that more inflammatory cytokine genes were expressed as the diseases increase in severity from non-cirrhotic ($p < 0.05$) to cirrhotic ($p < 0.05$) and even higher in the acute flare group ($p < 0.05$). This finding substantiates the role of the immune system in the progression of hepatitis B infection; the intensity of inflammatory response is concomitant with the physiological and pathological presentation of chronic hepatitis B patients.

DISCUSSION

In the present study, chronic hepatitis B patients were classified into three groups: non-cirrhotic, cirrhotic, and acute flare. The non-cirrhotic chronic hepatitis B patients were found to have significant upregulation of the interleukin 10 receptors (IL-10 R) 1 and 2, which provide binding sites for interleukin 10 (IL-10) to mediate its anti-inflammatory and hepatoprotective functions, in agreement with the finding of Zhang *et al* (6). IL-10 is a promoter of Th2 response; its upregulation in patients with chronic hepatitis B infection is of significant benefit as it is an anti-inflammatory cytokine that mediates its effects via B cells. Thus, it mediates viral clearance without having destructive effects on hepatocytes (7), which is supported by the findings of this study. Other upregulated genes associated with non-cirrhotic chronic hepatitis are colony stimulating factor 3 (CSF3) as reported previously in HCV infected patients (8), chemokine C-X3-C motif ligand 1 (CX3CL1) that was reported to enhance progressive liver fibrosis (9), and the cluster of differentiation 40 ligand (CD40LG) that is consistent with previous findings (10,11). G-CSF3 encodes a glycoprotein that supports the formation of haematopoietic colonies, thereby influencing the proliferation, survival, maturation of haematopoietic progenitors, and regulating the function of matured effector cells. Hence, G-CSF3 upregulation as also reported in this study is significant in preventing chronic non-cirrhotic patients from developing hepatocellular carcinoma this. However, similar studies have established the apoptotic effects of hepatocytes (12,13). The upregulation of the chemokine (C-C motif) ligand 1(CXCL1) gene, which is the only member of the CX3C chemokine family commonly known as fractalkine in humans, as found in this study to be associated with hepatic inflammation, is in agreement with similar previous findings (14,15). However, its function depends on its form; in the soluble form, it functions as a chemoattractant, while in the membrane form, it mediates the adhesion of leukocytes such as integrins (16,17). On the other hand, only chemokine (C-C motif) receptor 6 (CCR6) gene was found to be downregulated among the non-cirrhotic chronic hepatitis B patients; this gene encodes the CCR chemokine protein also referred to as cluster of differentiation 196 (CD196) (18) and has been reported to be associated with different diseases stages (19). It was also found to be associated with hepatic cirrhosis (20), as such its down-regulation may favor non-progression of chronic hepatitis B patients to cirrhosis and HCC, as revealed in this study and other related studies (21,22). In chronic hepatitis B patients with cirrhosis, upregulation of interleukin 3 (IL-3), a biological signalling cytokine that is capable of improving the body's natural response to diseases by binding to the IL-3 receptor and a member of the hematopoietic cytokines play significant role in the pathogenesis of malignancies as previously reported (23-25). Accordingly, upregulation of the IL-3 gene in liver cirrhotic patients indicates poor prognosis and may be associated with the development of HCC (26,27),

tumour necrosis factor (ligand) superfamily member 13 (TNFSF-13) in agreement with finding of Wu, Chen (28), chemokines such as the chemokine (C-C motif) ligand 4, and 26 (CCL4, CCL26) as reported to enhance the progression of liver cirrhosis to HCC in previous studies (29,30) and serve as a potential therapeutic target (31,32).

Similarly, chemokine (C-C motif) receptor 2 (CCR2) mediates the function of CC chemokines in regulating myeloid cell recruitment to the liver. The upregulation of chemokine suggests that myeloid cells recruited to the liver might lead to liver cirrhosis, as previously reported in non-alcoholic fatty liver diseases (33) and other related animal studies (34-36). Chemokine (C-X-C motif) ligand 9 (CXCL9) is a strong chemoattractant that plays a significant role in recruiting Th1 in chronic hepatitis C infection; this result is in agreement with the current study, wherein CXCL-9 was found to be significantly upregulated in hepatitis B liver cirrhosis (37,38).

A significant number of cytokine genes were also found to be downregulated in this study. Most important of them are IL-10Rb, Interferon alpha, TNF, CC chemokines, CXC chemokines family, and complement 5 (C5); others include IL-1, -5, -7, -8, -9, -15, -16, -17, -21, -27, and -33 (39,40). Among these cytokines, IL-10Rb which is an anti-inflammatory cytokine that mediates its effects via B cells, thereby mediating viral clearance without having destructive effects on the hepatocytes. Thus, it has been found significant in the clinical state of infection (41,42). Moreover, IL-10Rb downregulation in cirrhotic patients as revealed in this study is an indication of the significant role of this cytokine in preventing liver damage and the effect of its polymorphism (43) as well as its role in sustained virological response to PEGylated Interferon (44). Similarly, interferon alpha has been also considered as a cytokine with anti-viral, immunomodulatory, anti-fibrogenic, and anti-inflammatory activity, most especially in HCV infection (45,46). Therefore, its downregulation favors the cirrhotic state of the patients (47,48). The significant role it plays in the prevention of progression of chronic hepatitis B and C infection to cirrhosis makes it an important therapeutic agent.

The primary role of tumor necrosis factor (TNF) is to regulate immune cells; it is capable of inducing inflammation and inhibits tumorigenesis and viral replication (49). TNF and its related pro-inflammatory cytokines have been reported to play key roles in chronic infection (50,51), which concur with the findings in this study, according which modulating the TNF inflammatory pathway may have potential effects against pro-inflammatory diseases like viral hepatitis. Furthermore, the effects of CC chemokine are mediated by specific surface cell receptors (CCR1 to CCR10). The deletion of a CCR-2 receptor for CCL-2 in liver cells was found to be sufficient to inhibit a hepatic fibrogenic response (36) and has been associated with polarization of lymphocytes towards Th1 or Th2 (52). Similarly, CXC chemokine family includes CXCL-1 to CXCL-17; ligands of this receptor are highly expressed on organs that have a predilection for tumor metastasis (53). However, in this study, these genes were downregulated, which indicate poor patient condition as supported by previous studies (54,55). Complement 5 (C5) is the fifth component of the complement system, which plays a significant role in inflammation and has been reported to play a critical role in liver fibrosis (56). A similar study also reported an increased risk of fibrosis in hepatitis C patients (56-58). Tumour necrosis factor superfamily member 13 (TNFSF-13) on the other hand, was reported in a recent study to be associated with solid tumor pathogenesis (59), which is further supported by the findings of this study where significant upregulation was observed in cirrhotic patients but not in normal controls and non-cirrhotic patients.

Chronic hepatitis B acute flare has been reported to associate with pro-inflammatory cytokines as a result of systemic inflammatory response (60,61); the elevation of helper-2 (Th2)-associated cytokines like interleukin 4, 5, 10, and 13 has been also reported (62-64). However, in this study, only IL-1 receptor and some CC chemokines were found to be upregulated in acute flare patients, while other interleukins such as interferon-alpha, interferon-gamma, and TNFs were downregulated in line with the findings of other researchers (65,66). Spontaneous acute flare in chronic hepatitis B is a dynamic process of immune response involving the HBV, liver cells, and host immune cells. When the immune response to viral antigens is vigorous, it increases the prospect of inflammatory changes, leading to acute flare, and damage to the liver cells, leading to fibrosis (67). In conclusion, acute flare chronic hepatitis B patients were found to have the highest number of upregulated genes, most of which being chemokines. Chemokines associate with enhancing the inflammatory process, which might play a significant role in acute flaring of chronic hepatitis B patient. Non-cirrhotic chronic hepatitis B patients were found to significantly upregulate interleukin 10 receptor, which is a promoter of Th2 response. Upregulation of this receptor in patients with chronic hepatitis B infection is of significant benefit since it mediates its effects via B cells immune response thereby mediating viral clearance without having destructive effects on the hepatocytes. In cirrhotic chronic hepatitis B patients, the upregulated genes found in this study were interleukin 3 (IL-3), which is a biological signal cytokine capable of improving body's natural response to diseases by binding to the IL-3 receptor and is a member of hematopoietic cytokines.

ACKNOWLEDGEMENTS

Ethical approval to conduct this study was obtained from the Malaysian Medical Research Institute (NMRR-14-1136-21909) and the Malaysian Medical Research and Ethics Committee (KKM/NIHSEC/P15-63) as well as the Ethics Committee of the University Putra Malaysia Human (UPM/TNCPI/RMC/JKEUPM/1.4.18.1/F1). Informed consent was obtained from the patients by the attending physician. This work was supported by grant 5524778 from Fundamental Research Grant Scheme (FRGS) Malaysia.

REFERENCES

1. Dinarello CA. Biologic basis for interleukin-1 in disease. *Blood*. 1996; 87:2095-147.
2. Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. *Annu Rev Cell Dev Biol*. 1993; 9:317-43.
3. Norouzi M, Ghorashi SA, Ataei B, Yaran M, Malekzadeh R, Alavian SM, et al. Hepatitis B virus surface antigen variants clustered within immune epitopes in chronic hepatitis B carriers from Hormozgan Province, south of Iran. *Iran J Basic Med Sci*. 2010; 13:213-24.
4. Karamese M, Aydin H, Sengul E, Gelen V, Sevim C, Ustek D, et al. The Immunostimulatory Effect of Lactic Acid Bacteria in a Rat Model. *Iran J Immunol*. 2016; 13:220.
5. Liu Y, Yu J, Oaks Z, Marchena-Mendez I, Francis L, Bonilla E, et al. Liver injury correlates with biomarkers of autoimmunity and disease activity and represents an organ system involvement in patients with systemic lupus erythematosus. *Clin Immunol*. 2015; 160:319-27.

6. Zhang Z, Zhang S, Zou Z, Shi J, Zhao J, Fan R, et al. Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. *Hepatology*. 2011; 53:73-85.
7. Saraiva M, O'garra A. The regulation of IL-10 production by immune cells. *Nat Rev Immunol*. 2010; 10:170.
8. Durante-Mangoni E, Iardino P, Utili R, Adinolfi LE, Ruggiero G. Short communication Defective synthesis of granulocyte-colony stimulating factor in pegylated interferon- α treated chronic hepatitis C patients with declining leukocyte counts. *Antivir Ther*. 2006; 11:637-40.
9. Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. *Adv Drug Deliv Rev*. 2017.pii: S0169-409X(17)30063-7.
10. Weiskirchen R, Tacke F. Liver fibrosis: from pathogenesis to novel therapies. *Dig Dis*. 2016; 34:410-22.
11. Koyama Y, Brenner DA. Liver inflammation and fibrosis. *J Clin Invest*. 2017; 127:55-64.
12. Jiao J, Friedman SL, Aloman C. Hepatic fibrosis. *Curr Opin Gastroenterol*. 2009; 25:223.
13. Fishman P, Bar-Yehuda S, Farbstein T, Barer F, Ohana G. Adenosine acts as a chemoprotective agent by stimulating G-CSF production: a role for A 1 and A 3 adenosine receptors. *J Cell Physiol*. 2000; 183:393-8.
14. Bièche I, Asselah T, Laurendeau I, Vidaud D, Degot C, Paradis V, et al. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. *Virology*. 2005; 332:130-44.
15. Oo YH, Shetty S, Adams DH. The role of chemokines in the recruitment of lymphocytes to the liver. *Dig Dis*. 2010; 28:31-44.
16. Fong AM, Erickson HP, Zachariah JP, Poon S, Schamberg NJ, Imai T, et al. Ultrastructure and function of the fractalkine mucin domain in CX3C chemokine domain presentation. *J Biol Chem*. 2000; 275:3781-6.
17. Haskell CA, Cleary MD, Charo IF. Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. *J Biol Chem*. 1999; 274:10053-8.
18. Zola H, Swart B, Banham A, Barry S, Beare A, Bensussan A, et al. CD molecules 2006—human cell differentiation molecules. *J Immunol Methods*. 2007; 319:1-5.
19. Zhang H, Shi T, Zhao Y, Hua F, Zhang F. Tl1829 Elevated Inflammatory TH17 Cells in Primary Biliary Cirrhosis: the Source and Distribution and Role At Different Disease Stages. *Gastroenterology*. 2014; 146:S-1007-S-8.
20. Martínez-Esparza M, Tristán-Manzano M, Ruiz-Alcaraz AJ, García-Peñarrubia P. Inflammatory status in human hepatic cirrhosis. *World J Gastroenterol*. 2015; 21:11522.
21. Lefebvre E. Cenicriviroc For The Treatment Of Fibrosis. US Patent. 20,170,239,262; 2017.
22. Jiang X, Guo H, Shen T, Tang X, Yang Y, Ling W. Cyanidin-3-O- β -glucoside Purified from Black Rice Protects Mice against Hepatic Fibrosis Induced by Carbon Tetrachloride via Inhibiting Hepatic Stellate Cell Activation. *J Agric Food Chem*. 2015; 63:6221-30.
23. Ławicki S, Będkowska GE, Gacuta-Szumarska E, Szmitkowski M. Hematopoietic cytokines as tumor markers in gynecological malignancies: A multivariate analysis with ROC curve in endometrial cancer patients. *Growth Factors*. 2012; 30:29-36.
24. Kılınçalp S, Ekiz F, Başar Ö, Ayte MR, Çoban Ş, Yılmaz B, et al. Mean platelet volume could be possible biomarker in early diagnosis and monitoring of gastric cancer. *Platelets*. 2014; 25:592-4.
25. Łukaszewicz-Zajac M, Szmitkowski M, Litman-Zawadzka A, Mroczko B. Matrix Metalloproteinases and Their Tissue Inhibitors in Comparison to Other Inflammatory Proteins in Gastric Cancer (GC). *Cancer Invest*. 2016; 34:305-12.
26. Chan SL, Chan AW, Chan AK, Jian P, Mo F, Chan CM, et al. Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. *Liver Int*. 2017; 37:280-9.
27. Wasmer M-H, Krebs P. The Role of iL-33-Dependent inflammation in the Tumor Microenvironment. *Front Immunol*. 2017; 7:682.
28. Wu H, Chen P, Liao R, Li YW, Yi Y, Wang JX, et al. Intratumoral regulatory T cells with higher prevalence and more suppressive activity in hepatocellular carcinoma patients. *J Gastroenterol Hepatol*. 2013; 28:1555-64.
29. Liang C-M, Chen L, Hu H, Ma H-Y, Gao L-L, Qin J, et al. Chemokines and their receptors play important roles in the development of hepatocellular carcinoma. *World J Hepatol*. 2015; 7:1390.

30. Blümel J. Cancer and the Immune System. *Encyclopedia of Immunotoxicology*. 2016:133-8.
31. Liu B, Li J, Yan L-N. Chemokines in chronic liver allograft dysfunction pathogenesis and potential therapeutic targets. *Clin Dev Immunol*. 2013; 2013:325318.
32. Lillard Jr JW. Anti-CXCL9, anti-CXCL10, anti-CXCL11, anti-CXCL13, anti-CXCR3 and anti-CXCR5 agents for inflammatory disorders. *Google Patents*. 2013; US20120263733 A1.
33. Obstfeld AE, Sugaru E, Thearle M, Francisco A-M, Gayet C, Ginsberg HN, et al. CC chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. *Diabetes*. 2010; 59:916-25.
34. Yang S, IglayReger H, Kadouh H, Bodary P. Inhibition of the chemokine (C–C motif) ligand 2/chemokine (C–C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipotrophy. *Diabetologia*. 2009; 52:972-81.
35. Mitchell C, Couton D, Couty J-P, Anson M, Crain A-M, Bizet V, et al. Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice. *Am J Pathol*. 2009; 174:1766-75.
36. Seki E, De Minicis S, Inokuchi S, Taura K, Miyai K, Van Rooijen N, et al. CCR2 promotes hepatic fibrosis in mice. *Hepatology*. 2009; 50:185-97.
37. Tsai K-N, Kuo C-F, Ou J-HJ. Mechanisms of Hepatitis B Virus Persistence. *Trends Microbiol*. 2017.pii: S0966-842X(17)30176-2.
38. Iannacone M, Guidotti LG. Hepatitis B virus immunopathogenesis. *Hepatitis B Virus in Human Diseases*. Springer. 2016.p.79-93.
39. Lebossé F, Testoni B, Fresquet J, Facchetti F, Galmozzi E, Fournier M, et al. Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. *J Hepatol*. 2017; 66:897-909.
40. Li X, Liu X, Tian L, Chen Y. Cytokine-mediated immunopathogenesis of hepatitis B virus infections. *Clin Rev Allergy Immunol*. 2016; 50:41-54.
41. Romani S, Hosseini SM, Mohebbi SR, Boonstra A, Sharifian A. Differential expression of innate immune response genes in clinical phases of chronic hepatitis B infection. *J Viral Hepat*. 2017; 24:776-788.
42. van de Garde MD, Movita D, van der Heide M, Herschke F, De Jonghe S, Gama L, et al. Liver monocytes and kupffer cells remain transcriptionally distinct during chronic viral infection. *PloS one*. 2016; 11:e0166094.
43. Jin G, Kang H, Chen X, Dai D. Evaluation of the relationship between IL28B, IL10RB and IL28RA single-nucleotide polymorphisms and susceptibility to hepatitis C virus in Chinese Han population. *Infect Genet Evol*. 2014; 21:8-14.
44. Chandra P, Gunduz F, Hazari S, Kurt R, Panigrahi R. Impaired Expression of Type I and Type II Interferon Receptors in HCV-Associated Chronic Liver Disease and Liver Cirrhosis. *Plos One*. 2014; 9:e108616.
45. Vukobrat-Bijedic Z, Husic-Selimovic A, Mehinovic L, Mehmedovic A, Junuzovic D, Bjelogrić I, et al. Analysis of effect of antiviral therapy on regression of liver fibrosis in patient with HCV infection. *Mater Sociomed*. 2014; 26:172.
46. Simon TG, King LY, Zheng H, Chung RT. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. *J Hepatol*. 2015; 62:18-23.
47. MacParland SA, Corkum CP, Burgess C, Karwowska S, Kroll W, Michalak TI. Differential expression of interferon alpha inducible genes in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus and healthy donors. *Int Immunopharmacol*. 2015; 25:545-52.
48. Wandrer F, Falk CS, John K, Skawran B, Manns MP, Schulze-Osthoff K, et al. Interferon-Mediated Cytokine Induction Determines Sustained Virus Control in Chronic Hepatitis C Virus Infection. *J Infect Dis*. 2016; 213:746-54.
49. Chu W-M. Tumor necrosis factor. *Cancer Lett*. 2013; 328:222-5.
50. Waters JP, Pober JS, Bradley JR. Tumour necrosis factor in infectious disease. *The J Pathol*. 2013; 230:132-47.
51. Gupta SC, Tyagi AK, Deshmukh-Taskar P, Hinojosa M, Prasad S, Aggarwal BB. Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols. *Arch Biochem Biophys*. 2014; 559:91-9.
52. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. *Nature*. 2000; 404:407-11.
53. Coussens LM, Werb Z. Inflammation and cancer. *Nature*. 2002; 420:860-7.

54. Xu R, Bao C, Huang H, Lin F, Yuan Y, Wang S, et al. Low expression of CXCR1/2 on neutrophils predicts poor survival in patients with hepatitis B virus-related acute-on-chronic liver failure. *Sci Rep.* 2016; 6:38714.
55. Fahey S, Dempsey E, Long A. The role of chemokines in acute and chronic hepatitis C infection. *Cell Mol Immunol.* 2014; 11:25-40.
56. Hillebrandt S, Wasmuth HE, Weiskirchen R, Hellerbrand C, Keppeler H, Werth A, et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. *Nature Genet.* 2005; 37:835-43.
57. Hillebrandt S, Goos C, Matern S, Lammert F. Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus *Hfib1* on chromosome 15. *Gastroenterology.* 2002; 123:2041-51.
58. Vasel M, Rutz R, Bersch C, Feick P, Singer MV, Kirschfink M, et al. Complement activation correlates with liver necrosis and fibrosis in chronic hepatitis C. *Clin Immunol.* 2014; 150:149-56.
59. Wang R, Guo Y, Ma H, Feng L, Wang Q, Chen X, et al. Tumor necrosis factor superfamily member 13 is a novel biomarker for diagnosis and prognosis and promotes cancer cell proliferation in laryngeal squamous cell carcinoma. *Tumour Biol.* 2016; 37:2635-45.
60. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? *Atherosclerosis.* 2000; 148:209-14.
61. Jafarzadeh A, Bagheri-Jamebozorgi M, Nemati M, Golsaz-Shirazi F, Shokri F. Human Leukocyte Antigens Influence the Antibody Response to Hepatitis B Vaccine. *Iran J Allergy Asthma Immunol.* 2015; 14:233-45.
62. Pal R, Aggarwal R, Naik SR, Das V, Das S, Naik S. Immunological alterations in pregnant women with acute hepatitis E. *J Gastroenterol Hepatol.* 2005; 20:1094-101.
63. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. *J Interferon Cytokine Res.* 2009; 29:313-26.
64. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. *Nat Rev Immunol.* 2010; 10:103-10.
65. Wu HL, Kao JH, Chen TC, Wu WH, Liu CH, Su TH, et al. Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis B: clinical and mechanistic implications. *J Gastroenterol Hepatol.* 2014; 29:1629-36.
66. Joshi SS, Wong D, Castillo E, Swain MG, Coffin CS. Peripartum cytokine flares in a multiethnic cohort of chronic hepatitis B carriers does not correlate with hepatitis B virus suppression or increased risk of liver disease. *Am J Reprod Immunol.* 2017; 78.
67. Loggi E, Gamal N, Bihl F, Bernardi M, Andreone P. Adaptive response in hepatitis B virus infection. *J Viral Hepat.* 2014; 21:305-13.